Overview
The purpose of this study is to evaluate the long-term safety of trelagliptin tablets in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal failure in the routine clinical setting.
Description
The drug being tested in this study is called trelagliptin tablet. This tablet is being tested to treat people who have type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal failure.
This study is an observational (non-interventional) study and will look at the long-term safety of the trelagliptin tablet in the routine clinical setting. The planned number of observed patients will be approximately 100.
This multi-center observational trial will be conducted in Japan.
Eligibility
Inclusion Criteria:
- Participants must be type 2 diabetes mellitus patients meeting the following conditions:
Have severe renal impairment or end-stage renal disease, with serum creatinine (mg/dL) or
creatinine clearance (Ccr; mL/min) meeting the following criteria within 3 months before
the start of treatment with this product
- Serum creatinine (mg/dL)*: male: > 2.4, female: > 2.0
- Ccr (mL/min): < 30 In patients with end-stage renal disease, this product may be administered irrespective of the time of hemodialysis.
- Estimated values corresponding to the Ccr (for persons aged 60 years weighing 65 kg)
Exclusion Criteria:
- Participants with any of the following contraindications for trelagliptin will be excluded
- Patient with severe ketosis, diabetic coma or pre-coma, or type 1 diabetes mellitus
- Patient with severe infection, perioperative status, or serious trauma
- Patient with a history of hypersensitivity to any ingredients of trelagliptin